GlobeNewswire by notified

Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024

Share

Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders’ Meeting.

The Combined Shareholders' Meeting was held on Thursday June 20, 2024 at 9 a.m. at Hôtel Castel Burgond, 3 route de Troyes, 21121 Daix (France), under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva.

Mr. Frederic Cren proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the Bureau by appointing Mr. Pierre Broqua and Mr. Jean Volatier, as tellers, as well as Mr. Dorian Raynaldy, as secretary of the general meeting.

All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 30th resolution, which had been the subject of a negative recommendation by the Board of Directors. The 30th resolution would have empowered the Board of Directors to decide on share capital increases reserved for members of a company savings plan to be set up by the Company.

Pursuant to Article R. 22-10-14 IV. of the French Commercial Code, the Combined Shareholders’ Meeting approved, without modification, the compensation policy for corporate officers as presented in the 2023 Universal Registration Document (Part 3.5.1, pages 147 and seq.).

Information on the results of the votes is detailed below:

  • Total number of shares composing the share capital: 52 477 188
  • Total number of shares with voting rights: 52 346 516


Ordinary partExtraordinary part
ShareholdersSharesVotesShareholdersSharesVotes
Shareholders present 3 14 120 14 120 3 14 120 14 120
Proxy to third parties 0 0 0 0 0 0
Proxy to the Chairman 146 4 203 203 4 285 983 146 4 203 203 4 285 983
Mail votes 67 28 881 338 41 012 196 67 28 881 338 41 012 196
TOTAL 216 33 098 661 45 312 299 216 33 098 661 45 312 299
Quorum 63,229 % 63,229 %
VOTE RESULTS
Ordinary Resolutions

ResolutionResultForAgainstAbstentionTotal number of votes castNumber of represented sharesProportion of represented share capitalNon- voting votesInvalid votesQuorum
Votes%Votes%Votes%
1 Adopted

44 619 134


> 99,99 %


3 250


< 0,01 %


689 915
­
-



44 622 384


33 098 661


63,072 %


0


0


63,229 %
2 Adopted 44 619 134 > 99,99 % 3 250 < 0,01 % 689 915 ­- 44 622 384 33 098 661 63,072 % 0 0 63,229 %
3 Adopted 44 615 618 99,98 % 6 765 0,02 % 689 916 44 622 383 33 098 661 63,072 % 0 0 63,229 %
4 Adopted 44 611 047 99,98 % 11 045 0,02 % 690 207 44 622 092 33 098 661 63,072 % 0 0 63,229 %
5 Adopted 36 839 472 99,95 % 17 456 0,05 % 690 371 36 856 928 29 216 161 55,674 % 7 765 000 0 60,284 %
6 Adopted 43 770 264 98,09 % 851 680 1,91 % 690 355 ­-­ 44 621 944 33 098 661 63,072 % 0 0 63,229 %
7 Adopted 44 524 341 99,78 % 97 398 0,22 % 690 560 ­-­ 44 621 739 33 098 661 63,072 % 0 0 63,229 %
8 Adopted 43 765 599 98,08 % 856 115 1,92 % 690 585 ­- 44 621 714 33 098 661 63,072 % 0 0 63,229 %
9 Adopted 44 025 261 98,66 % 596 483 1,34 % 690 555 ­- 44 621 744 33 098 661 63,072 % 0 0 63,229 %
10 Adopted 43 765 701 98,08 % 855 278 1,92 % 691 320 ­- 44 620 979 33 098 661 63,072 % 0 0 63,229 %
11 Adopted 43 765 701 98,08 % 855 278 1,92 % 691 320 ­- 44 620 979 33 098 661 63,072 % 0 0 63,229 %
12 Adopted 43 747 961 98,08 % 854 150 1,92 % 710 188 ­- 44 602 111 33 098 661 63,072 % 0 0 63,229 %
13 Adopted 44 508 017 99,79 % 94 379 0,21 % 709 903 ­- 44 602 396 33 098 661 63,072 % 0 0 63,229 %
14 Adopted 43 861 062 98,29 % 762 113 1,71 % 689 124 ­- 44 623 175 33 098 661 63,072 % 0 0 63,229 %
15 Adopted 44 579 434 99,90 % 43 446 0,10 % 689 419 ­- 44 622 880 33 098 661 63,072 % 0 0 63,229 %
16 Adopted 44 580 234 99,90 % 42 616 0,10 % 689 449 ­- 44 622 850 33 098 661 63,072 % 0 0 63,229 %
17 Adopted 44 578 834 99,90 % 44 016 0,10 % 689 449 ­- 44 622 850 33 098 661 63,072 % 0 0 63,229 %
18 Adopted 44 328 422 99,34 % 295 698 0,66 % 688 179 ­- 44 624 120 33 098 661 63,072 % 0 0 63,229 %
19 Adopted 44 145 753 98,93 % 478 643 1,07 % 687 903 ­- 44 624 396 33 098 661 63,072 % 0 0 63,229 %
37 Adopted 44 610 785 99,97 % 12 336 0,03 % 689 178 ­- 44 623 121 33 098 661 63,072 % 0 0 63,229 %
VOTE RESULTS
Extraordinary Resolutions

ResolutionResultForAgainstAbstentionTotal number of votes castNumber of represented sharesProportion of represented share capitalNon-voting votesInvalid votesQuorum
Votes%Votes%Votes%
20Adopted44 359 75999,41 %263 7270,59 %688 813­-44 623 48633 098 66163,072 %0063,229 %
21Adopted43 798 80698,16 %822 7641,84 %690 729­-44 621 57033 098 66163,072 %0063,229 %
22Adopted43 781 84198,15 %827 2691,85 %703 189­-44 609 11033 098 66163,072 %0063,229 %
23Adopted43 782 04198,15 %826 8391,85 %703 419­-44 608 88033 098 66163,072 %0063,229 %
24Adopted43 796 06798,15 %827 3131,85 %688 919­-44 623 38033 098 66163,072 %0063,229 %
25Adopted43 795 68698,15 %827 6941,85 %688 919­-44 623 38033 098 66163,072 %0063,229 %
26Adopted43 799 38698,15 %823 9941,85 %688 919­-44 623 38033 098 66163,072 %0063,229 %
27Adopted43 793 24398,14 %830 3331,86 %688 723­-44 623 57633 098 66163,072 %0063,229 %
28Adopted43 797 95398,15 %825 6231,85 %688 723­-44 623 57633 098 66163,072 %0063,229 %
29Adopted43 794 81198,15 %825 8241,85 %691 664­-44 620 63533 098 66163,072 %0063,229 %
30Rejected13 056 81433,91 %25 451 08566,09 %6 804 400­-38 507 89933 098 66163,072 %0063,229 %
31Adopted44 583 64499,92 %35 8960,08 %692 759­-44 619 54033 098 66163,072 %0063,229 %
32Adopted43 812 12398,18 %810 5761,82 %689 600­-44 622 69933 098 66163,072 %0063,229 %
33Adopted43 790 73898,13 %832 7611,87 %688 800­-44 623 49933 098 66163,072 %0063,229 %
34Adopted43 753 65098,05 %869 7261,95 %688 923­-44 623 37633 098 66163,072 %0063,229 %
35Adopted44 598 71499,95 %20 9650,05 %692 620­-44 619 67933 098 66163,072 %0063,229 %
36Adopted44 039 96298,69 %582 8081,31 %689 529­-44 622 77033 098 66163,072 %0063,229 %

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.

Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease.

Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com

Contacts

Inventiva

Pascaline Clerc, PhD
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
   +1 202 499 8937
Brunswick Group
Tristan Roquet Montegon /
Aude Lepreux /
Julia Cailleteau
Media relations
inventiva@brunswickgroup.com

   +33 1 53 96 83 83
Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com

         +1 415 513-1284

Important Notice

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements.

These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s pre-clinical programs and clinical trials, including design, duration, timing, recruitment costs, screening and enrollment for those trials, including the ongoing NATiV3 Phase III clinical trial with lanifibranor in MASH/NASH, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva’s product candidates, including lanifibranor, potential regulatory submissions, approvals and commercialization, Inventiva’s pipeline and preclinical and clinical development plans, the expected benefit of having received Breakthrough Therapy Designation, including its impact on the development and review timeline of Inventiva’s product candidates, the potential development of and regulatory pathway for odiparcil, and future activities, expectations, plans, growth and prospects of Inventiva and its partners. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”, “opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on enrollment or the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’s ability to obtain financing and to enter into potential transactions, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners’ clinical trials may not support Inventiva's and its partners’ product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’s clinical trials, Inventiva’s expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners’ control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s and its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva’s and its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2023, filed with the Autorité des Marchés Financiers on April 3, 2024, and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission on April 3, 2024. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.

Attachment

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

HiddenA line styled icon from Orion Icon Library.Eye